Log in

NASDAQ:NTECIntec Pharma Stock Price, Forecast & News

+0.03 (+8.03 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $0.42
50-Day Range
MA: $0.35
52-Week Range
Now: $0.42
Volume10.72 million shs
Average Volume6.25 million shs
Market Capitalization$29.07 million
P/E RatioN/A
Dividend YieldN/A
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various indications, including low back pain, neuropathic pain, and fibromyalgia. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.
Read More
Intec Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.21 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:NTEC



Sales & Book Value

Annual SalesN/A
Book Value$0.22 per share


Net Income$-47,600,000.00


Market Cap$29.07 million
Next Earnings Date11/10/2020 (Estimated)
+0.03 (+8.03 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NTEC News and Ratings via Email

Sign-up to receive the latest news and ratings for NTEC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Intec Pharma (NASDAQ:NTEC) Frequently Asked Questions

How has Intec Pharma's stock been impacted by COVID-19 (Coronavirus)?

Intec Pharma's stock was trading at $0.2388 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NTEC shares have increased by 75.8% and is now trading at $0.4197.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Intec Pharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intec Pharma in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Intec Pharma

When is Intec Pharma's next earnings date?

Intec Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Intec Pharma

How were Intec Pharma's earnings last quarter?

Intec Pharma Ltd (NASDAQ:NTEC) issued its quarterly earnings results on Wednesday, August, 5th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.00.
View Intec Pharma's earnings history

What price target have analysts set for NTEC?

4 equities research analysts have issued 1 year price targets for Intec Pharma's shares. Their forecasts range from $1.00 to $1.00. On average, they expect Intec Pharma's stock price to reach $1.00 in the next twelve months. This suggests a possible upside of 138.3% from the stock's current price.
View analysts' price targets for Intec Pharma

Has Intec Pharma been receiving favorable news coverage?

Media stories about NTEC stock have been trending very positive this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Intec Pharma earned a news impact score of 4.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about Intec Pharma

Who are some of Intec Pharma's key competitors?

What other stocks do shareholders of Intec Pharma own?

Who are Intec Pharma's key executives?

Intec Pharma's management team includes the following people:
  • Mr. Jeffrey A. Meckler, Vice Chairman & CEO (Age 53, Pay $786.9k)
  • Mr. Nir Sassi, Chief Financial Officer (Age 44, Pay $338.11k)
  • Dr. Nadav Navon Ph.D., Chief Operating Officer (Age 51, Pay $394.94k)
  • Mr. Walt Addison Linscott, Chief Bus. Officer (Age 59, Pay $557.05k)
  • Dr. R. Michael Gendreau, Chief Medical Officer (Age 64, Pay $459.15k)

When did Intec Pharma IPO?

(NTEC) raised $30 million in an initial public offering (IPO) on Tuesday, August 4th 2015. The company issued 5,000,000 shares at $6.00 per share. Maxim Group and Roth Capital Partners served as the underwriters for the IPO.

What is Intec Pharma's stock symbol?

Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC."

Who are Intec Pharma's major shareholders?

Intec Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include Integrated Wealth Concepts LLC (0.60%), Harel Insurance Investments & Financial Services Ltd. (0.53%) and Russell Investments Group Ltd. (0.15%). Company insiders that own Intec Pharma stock include Anthony J Maddaluna, Issac Silberman, Jeffrey A Meckler and Pharma Technologies Ltd Dexcel.
View institutional ownership trends for Intec Pharma

Which institutional investors are buying Intec Pharma stock?

NTEC stock was bought by a variety of institutional investors in the last quarter, including Integrated Wealth Concepts LLC, Harel Insurance Investments & Financial Services Ltd., and Russell Investments Group Ltd.. Company insiders that have bought Intec Pharma stock in the last two years include Anthony J Maddaluna, and Jeffrey A Meckler.
View insider buying and selling activity for Intec Pharma

How do I buy shares of Intec Pharma?

Shares of NTEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Intec Pharma's stock price today?

One share of NTEC stock can currently be purchased for approximately $0.42.

How big of a company is Intec Pharma?

Intec Pharma has a market capitalization of $29.07 million. The biotechnology company earns $-47,600,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. Intec Pharma employs 38 workers across the globe.

What is Intec Pharma's official website?

The official website for Intec Pharma is www.intecpharma.com.

How can I contact Intec Pharma?

Intec Pharma's mailing address is 12 HARTOM STREET HAR HOTZVIM, JERUSALEM L3, 777512. The biotechnology company can be reached via phone at 972-2586-4657 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.